Cantharidin and norcantharidin impair stemness of pancreatic cancer cells by repressing the β-catenin pathway and strengthen the cytotoxicity of gemcitabine and erlotinib

International Journal of Oncology

Volumn 47, Issue 5, 2015, Pages 1912-1922

  Wang, Wen Jie ^a   Wu, Meng Yao ^a   Shen, Meng ^a   Zhi, Qiaoming ^a   Liu, Ze Yi ^a   Gong, Fei Ran ^a   Tao, Min ^a,b,c   Li, Wei ^a  

^a SOOCHOW UNIVERSITY   (China)

^b MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

^c Institute of Clinical Immunology of Jiangsu Province   (China)

Author keywords

Cancer stem cells; Cantharidin; Pancreatic cancer; PP2A; catenin

Indexed keywords

ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; BETA CATENIN; BMI1 PROTEIN; CANTHARIDIN; CD24 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; CYSTEINE RICH PROTEIN 61; EPHRIN RECEPTOR A2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPITHELIAL CELL ADHESION MOLECULE; ERLOTINIB; GEMCITABINE; HERMES ANTIGEN; HIGH MOBILITY GROUP A2 PROTEIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; KRUPPEL LIKE FACTOR 4; KRUPPEL LIKE FACTOR 5; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; NORCANTHARIDIN; SMAD3 PROTEIN; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR HES 1; TRANSCRIPTION FACTOR MSX2; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2; TRANSCRIPTION FACTOR SOX9; DEOXYCYTIDINE; FUSED HETEROCYCLIC RINGS;

ARTICLE; CANCER CELL; CANCER GROWTH; CANCER RESISTANCE; CLONOGENESIS; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EXPOSURE; DRUG POTENTIATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LONG TERM EXPOSURE; MICROARRAY ANALYSIS; MTT ASSAY; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; ANALOGS AND DERIVATIVES; APOPTOSIS; CANCER STEM CELL; CELL PROLIFERATION; DRUG EFFECTS; GENETICS; PANCREATIC NEOPLASMS; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

APOPTOSIS; BETA CATENIN; BICYCLO COMPOUNDS, HETEROCYCLIC; CANTHARIDIN; CELL LINE, TUMOR; CELL PROLIFERATION; DEOXYCYTIDINE; ERLOTINIB HYDROCHLORIDE; HUMANS; NEOPLASTIC STEM CELLS; PANCREATIC NEOPLASMS; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 84942846318     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2015.3156     Document Type: Article

References (64)

1. Wang SJ, Gao Y, Chen H, Kong R, Jiang HC, Pan SH, Xue DB, Bai XW and Sun B: Dihydroartemisinin inactivates NF-kappaB and potentiates the anti-tumor effect of gemcitabine on pancreatic cancer both in vitro and in vivo. Cancer Lett 293: 99-108, 2010.
2. Li D, Xie K, Wolff R and Abbruzzese JL: Pancreatic cancer. Lancet 363: 1049-1057, 2004.
3. Guo X and Cui Z: Current diagnosis and treatment of pancreatic cancer in China. Pancreas 31: 13-22, 2005.
4. Bardeesy N and DePinho RA: Pancreatic cancer biology and genetics. Nat Rev Cancer 2: 897-909, 2002.
5. Bednar F and Simeone DM: Pancreatic cancer stem cell biology and its therapeutic implications. J Gastroenterol 46: 1345-1352, 2011.
6. Castellanos JA, Merchant NB and Nagathihalli NS: Emerging targets in pancreatic cancer: Epithelial-mesenchymal transition and cancer stem cells. Onco Targets Ther 6: 1261-1267, 2013.
7. Xia J, Chen C, Chen Z, Miele L, Sarkar FH and Wang Z: Targeting pancreatic cancer stem cells for cancer therapy. Biochim Biophys Acta 1826: 385-399, 2012.
8. Wang GS: Medical uses of mylabris in ancient China and recent studies. J Ethnopharmacol 26: 147-162, 1989.
9. Li W, Xie L, Chen Z, Zhu Y, Sun Y, Miao Y, Xu Z and Han X: Cantharidin, a potent and selective PP2A inhibitor, induces an oxidative stress-independent growth inhibition of pancreatic cancer cells through G2/M cell-cycle arrest and apoptosis. Cancer Sci 101: 1226-1233, 2010.
10. Li W, Chen Z, Zong Y, Gong F, Zhu Y, Zhu Y, Lv J, Zhang J, Xie L, Sun Y, et al: PP2A inhibitors induce apoptosis in pancreatic cancer cell line PANC-1 through persistent phosphorylation of IKKα and sustained activation of the NF-κB pathway. Cancer Lett 304: 117-127, 2011.
11. Li W, Chen Z, Gong FR, Zong Y, Chen K, Li DM, Yin H, Duan WM, Miao Y, Tao M, et al: Growth of the pancreatic cancer cell line PANC-1 is inhibited by protein phosphatase 2A inhibitors through overactivation of the c-Jun N-terminal kinase pathway. Eur J Cancer 47 2654-2664, 2011.
12. Wu MY, Xie X, Xu ZK, Xie L, Chen Z, Shou LM, Gong FR, Xie YF, Li W and Tao M: PP2A inhibitors suppress migration and growth of PANC-1 pancreatic cancer cells through inhibition on the Wnt/β-catenin pathway by phosphorylation and degradation of β-catenin. Oncol Rep 32: 513-522, 2014
13. Xie X, Wu MY, Shou LM, Chen LP, Gong FR, Chen K, Li DM, Duan WM, Xie YF, Mao YX, et al: Tamoxifen enhances the anticancer effect of cantharidin and norcantharidin in pancreatic cancer cell lines through inhibition of the protein kinase C signaling pathway. Oncol Lett 9: 837-844, 2015
14. Honkanen RE: Cantharidin, another natural toxin that inhibits the activity of serine/threonine protein phosphatases types 1 and 2A. FEBS Lett 330: 283-286, 1993.
15. Prakash N and Wurst W: A Wnt signal regulates stem cell fate and differentiation in vivo. Neurodegener Dis 4: 333-338, 2007
16. Cui J, Jiang W, Wang S, Wang L and Xie K: Role of Wnt/β-catenin signaling in drug resistance of pancreatic cancer. Curr Pharm. Des 18: 2464-2471, 2012.
17. Gresham GK, Wells GA, Gill S, Cameron C and Jonker DJ: Chemotherapy regimens for advanced pancreatic cancer: A systematic review and network meta-analysis. BMC Cancer 14: 471, 2014
18. Shou LM, Zhang QY, Li W, Xie X, Chen K, Lian L, Li ZY, Gong FR, Dai KS, Mao YX, et al: Cantharidin and norcantharidin inhibit the ability of MCF-7 cells to adhere to platelets via protein kinase C pathway-dependent downregulation of α2 integrin. Oncol Rep 30: 1059-1066, 2013.
19. Reghunathan R, Bi C, Liu SC, Loong KT, Chung TH, Huang G and Chng WJ: Clonogenic multiple myeloma cells have shared stemness signature associated with patient survival. Oncotarget 4: 1230-1240, 2013.
20. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF and Simeone DM: Identifcation of pancreatic cancer stem cells. Cancer Res 67: 1030-1037, 2007
21. Jemal A, Siegel R, Xu J and Ward E Cancer statistics, 2010. CA Cancer J Clin 60: 277-300, 2010.
22. Lee CJ, Li C and Simeone DM: Human pancreatic cancer stem cells: Implications for how we treat pancreatic cancer. Transl Oncol 1: 14-18, 2008.
23. Hong SP, Wen J, Bang S, Park S and Song SY CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells. Int J Cancer 125: 2323-2331, 2009
24. low/HER2low breast cancer stem cells. Cancer Res 69: 8058-8066, 2009
25. Yabuuchi S, Pai SG, Campbell NR, de Wilde RF, De Oliveira E, Korangath P, Streppel MM, Rasheed ZA, Hidalgo M, Maitra A, et al: Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer. Cancer Lett 335: 41-51, 2013.
26. Bonnet D and Dick JE: Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3: 730-737, 1997
27. Li C, Wu JJ, Hynes M, Dosch J, Sarkar B, Welling TH, Pasca di Magliano M and Simeone DM.: c-Met is a marker of pancreatic cancer stem cells and therapeutic target. Gastroenterology 141: 2218-2227 e2215, 2011.
28. Rasheed ZA and Matsui W: Biological and clinical relevance of stem cells in pancreatic adenocarcinoma. J Gastroenterol Hepatol 27 (Suppl 2): S15-S18, 2012.
29. Richard V, Nair MG, Santhosh Kumar TR and Pillai MR: Side population cells as prototype of chemoresistant, tumor-initiating cells. BioMed Res Int 2013: 517237, 2013.
30. Marhaba R, Klingbeil P, Nuebel T, Nazarenko I, Buechler MW and Zoeller M: CD44 and EpCAM: Cancer-initiating cell markers. Curr Mol Med 8: 784-804, 2008.
31. Naor D, Nedvetzki S, Golan I, Melnik L and Faitelson Y CD44 in cancer. Crit Rev Clin Lab Sci 39: 527-579, 2002.
32. Jothy S: CD44 and its partners in metastasis. Clin Exp Metastasis 20: 195-201, 2003.
33. Klingbeil P, Marhaba R, Jung T, Kirmse R, Ludwig T and Zöller M: CD44 variant isoforms promote metastasis formation by a tumor cell-matrix cross-talk that supports adhesion and apoptosis resistance. Mol Cancer Res 7: 168-179, 2009.
34. Malanchi I, Peinado H, Kassen D, Hussenet T, Metzger D, Chambon P, Huber M, Hohl D, Cano A, Birchmeier W, et al: Cutaneous cancer stem cell maintenance is dependent on beta-catenin signalling. Nature 452: 650-653, 2008.
35. Chong JM and Speicher DW: Determination of disulfde bond assignments and N-glycosylation sites of the human gastrointestinal carcinoma antigen GA733-2 (CO17-1A, EGP, KS1-4, KSA, and Ep-CAM). J Biol Chem 276: 5804-5813, 2001.
36. Trebak M, Begg GE, Chong JM, Kanazireva EV, Herlyn D and Speicher DW: Oligomeric state of the colon carcinoma-associated glycoprotein GA733-2 (Ep-CAM/EGP40) and its role in GA733-mediated homotypic cell-cell adhesion. J Biol Chem 276: 2299-2309, 2001.
37. Mohan A, Nalini V, Mallikarjuna K, Jyotirmay B and Krishnakumar S: Expression of motility-related protein MRP1/ CD9, N-cadherin, E-cadherin, alpha-catenin and beta-catenin in retinoblastoma. Exp Eye Res 84: 781-789, 2007.
38. Yamashita T, Budhu A, Forgues M and Wang XW: Activation of hepatic stem cell marker EpCAM by Wnt-beta-catenin signaling in hepatocellular carcinoma. Cancer Res 67: 10831-10839, 2007.
39. Guillemot JC, Naspetti M, Malergue F, Montcourrier P, Galland F and Naquet P: Ep-CAM transfection in thymic epithelial cell lines triggers the formation of dynamic actin-rich protrusions involved in the organization of epithelial cell layers. Histochem Cell Biol 116: 371-378, 2001.
40. Münz M, Kieu C, Mack B, Schmitt B, Zeidler R and Gires O: The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation. Oncogene 23: 5748-5758, 2004.
41. Osta WA, Chen Y, Mikhitarian K, Mitas M, Salem M, Hannun YA, Cole DJ and Gillanders WE: EpCAM is overex-pressed in breast cancer and is a potential target for breast cancer gene therapy. Cancer Res 64: 5818-5824, 2004.
42. Baeuerle PA and Gires O: EpCAM (CD326) fnding its role in cancer. Br J Cancer 96: 417-423, 2007.
43. Oonishi K, Cui X, Hirakawa H,, Fujimori A, Kamijo T, Yamada S, Yokosuka O and Kamada T: Different effects of carbon ion beams and X-rays on clonogenic survival and DNA repair in human pancreatic cancer stem-like cells. Radiother Oncol 105: 258-265, 2012.
44. Ohara Y, Oda T, Sugano M, Hashimoto S, Enomoto T, Yamada K, Akashi Y, Miyamoto R, Kobayashi A, Fukunaga K, et al: Histological and prognostic importance of CD44(+) /CD24(+) / EpCAM(+) expression in clinical pancreatic cancer. Cancer Sci 10 4: 1127-1134, 2013.
45. Herreros-Villanueva M, Zubia-Olascoaga A and Bujanda L: c-Met in pancreatic cancer stem cells: Therapeutic implications. World J Gastroenterol 18: 5321-5323, 2012.
46. Rasheed ZA, Yang J, Wang Q, Kowalski J, Freed I, Murter C, Hong SM, Koorstra JB, Rajeshkumar N V, He X, et al: Prognostic signifcance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. J Natl Cancer Inst 102: 340-351, 2010.
47. Ding Q, Miyazaki Y, Tsukasa K, Matsubara S, Yoshimitsu M and Takao S: CD133 facilitates epithelial-mesenchymal transition through interaction with the ERK pathway in pancreatic cancer metastasis. Mol Cancer 13: 15, 2014.
48. Clevers H: Wnt/beta-catenin signaling in development and disease. Cell 127: 469-480, 2006.
49. Andrade AC, Nilsson O, Barnes KM and Baron J: Wnt gene expression in the post-natal growth plate: Regulation with chon-drocyte differentiation. Bone 40: 1361-1369, 2007.
50. Shafee N, Smith CR, Wei S, Kim Y, Mills GB, Hortobagyi GN, Stanbridge EJ and Lee EY: Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors. Cancer Res 68: 3243-3250, 2008.
51. Todaro M, Alea M P, Di Stefano AB, Cammareri P, Vermeulen L, Iovino F, Tripodo C, Russo A, Gulotta G, Medema J P, et al: Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 1: 389-402, 2007.
52. Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, Hilsenbeck SG, Pavlick A, Zhang X, Chamness GC, et al: Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 100: 672-679, 2008.
53. Jemal A, Siegel R, Ward E, Murray T, Xu J and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin 57: 43-66, 2007.
54. Ciliberto D, Botta C, Correale P, Rossi M, Caraglia M, Tassone P and Tagliaferri P: Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: A meta-analysis of randomised trials. Eur J Cancer 49: 593-603, 2013.
55. Ko AH, Dito E, Schillinger B, Venook A P, Xu Z, Bergsland EK, Wong D, Scott J, Hwang J and Tempero MA: A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: Is an anti-VEGF strategy still applicable? Invest New Drugs 26: 463-471, 2008.
56. Nedaeinia R, Avan A, Manian M, Salehi R and Ghayour-Mobarhan M: EGFR as a potential target for the treatment of pancreatic cancer: Dilemma and controversies. Curr Drug Targets 15: 1293-1301, 2014.
57. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart J W, Guba M, Bruns CJ and Heeschen C: Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1: 313-323, 2007.
58. Lee CJ, Dosch J and Simeone DM: Pancreatic cancer stem cells. J Clin Oncol 26: 2806-2812, 2008.
59. Seguin L, Kato S, Franovic A, Camargo MF, Lesperance J, Elliott KC, Yebra M, Mielgo A, Lowy AM, Husain H, et al: An integrin β3-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition. Nat Cell Biol 16: 457-468, 2014.
60. Yilmaz OH, Valdez R, Theisen BK, Guo W, Ferguson DO, Wu H and Morrison SJ: Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 441: 475-482, 2006.
61. Jin L, Hope KJ, Zhai Q, Smadja-Joffe F and Dick JE: Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 12: 1167-1174, 2006.
62. Jones RJ, Matsui WH and Smith BD: Cancer stem cells: Are we missing the target? J Natl Cancer Inst 96: 583-585, 2004.
63. Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA and Lander ES: Identifcation of selective inhibitors of cancer stem cells by high-throughput screening. Cell 138: 645-659, 2009.
64. Dingli D and Michor F: Successful therapy must eradicate cancer stem cells. Stem Cells 24: 2603-2610, 2006.